MPH Health Care AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 6/4/2026)
| Balance Sheet | Total Assets | 258,085,732.00 | ROE | 94.31 % |
| Balance Sheet | Total Equity | 243,405,127.00 | ROA | -11.36 % |
| Cashflow | Capital Expenditures | -7,861.00 | P/FCF | 984.87 |
| Cashflow | Free Cash Flow | 123,014.00 | – | – |
| Cashflow | Operating Cash Flow | 130,875.00 | P/CF | 925.71 |
| Income | Earnings per Share (diluted) | -6.85 | Div. Yield | – |
| Income | Net Income | -29,327,624.00 | P/E | -4.13 |
| Income | Shares Outstanding | 4,281,000.00 | P/B | 0.50 |
| Income | Total Revenue | 364,300,000.00 | P/S | 33.45 |
Ratios calculated on: 10/14/2026
Company Description
MPH Mittelstaendische Pharma Holding AG is a German-based company engaged, through its subsidiaries, in the development, production, licensing, and sale of generics in Germany. The Company also involves in the licensing and import of patent protected EU branded pharmaceuticals. Its product line includes pharmaceutical products for oncology, HIV, neurology, rheumatism, cardiovascular, lifestyle medicine, and rheumatology. The Company also provides veterinary pharmaceutical and medical products, as well as animal complement feed. Its veterinary products primarily focus on horse therapy treatment, which comprise products for the musculoskeletal system and immune system.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.mph-ag.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more